Sotoxen 120 MG (Sotorasib)

Basic Product Information of Sotoxen (Sotorasib) 120mg

How Sotoxen (Sotorasib) Works

Sotoxen contains Sotorasib, a potent and highly selective inhibitor of KRAS G12C (Kirsten rat sarcoma viral oncogene homolog, glycine-12-to-cysteine mutant), an oncogenic driver found across several cancer types, most notably a subset of NSCLC. Unlike wild-type KRAS, the G12C mutant protein carries a reactive cysteine residue that Sotorasib exploits, forming a permanent covalent bond that irreversibly deactivates the protein.

Sotorasib’s potency and selectivity come from binding both the P2 pocket and the His95 surface groove of KRAS G12C, locking the protein in its inactive, GDP-bound state. This prevents the abnormal downstream signalling that would otherwise drive tumour cell proliferation and survival, inhibiting tumour growth and promoting apoptosis (programmed cell death) selectively in tumours carrying the G12C mutation, while leaving normal, wild-type KRAS unaffected.

Sotoxen is taken as a once-daily oral tablet, and treatment is only appropriate for patients whose tumours have been confirmed to carry the KRAS G12C mutation using an approved diagnostic test.

Indication for Sotoxen (Sotorasib)

Sotoxen (Sotorasib) is indicated for the following condition:

Benefits of Sotoxen (Sotorasib) 120mg

How to Take Sotoxen (Sotorasib)

Monitoring and Dosage Adjustments

Regular monitoring is essential throughout Sotoxen treatment. Your oncologist will check liver function tests before starting treatment, every 3 weeks during the first 3 months, then monthly thereafter, or more frequently if abnormalities are found. Monitoring also includes prompt evaluation of any new or worsening respiratory symptoms suggestive of interstitial lung disease, and ECG monitoring in patients at risk of QT prolongation. Report any yellowing of the skin or eyes, unusual fatigue, breathlessness, cough, fever, dizziness, or palpitations to your doctor immediately.

Drug Interactions and Important Information

Avoid coadministration of Sotoxen with gastric acid-reducing agents, including proton pump inhibitors, H2-receptor antagonists, and antacids, as these reduce Sotoxen absorption and effectiveness. Avoid coadministration with sensitive P-glycoprotein (P-gp) substrate medications where small concentration changes could cause serious toxicity; if unavoidable, the dose of the P-gp substrate medication may need to be reduced, per that medication’s own prescribing information.

Sotorasib is a moderate CYP3A4 inducer and may reduce the effectiveness of certain CYP3A4 substrate medications, including hormonal contraceptives; non-hormonal contraception is generally recommended during treatment and for a period after the final dose. Always inform your physician of all medications, supplements, and herbal products you are currently taking before starting Sotoxen.

Side Effects and Precautions

Who Should Use Sotoxen (Sotorasib)?

Sotoxen is suitable for adult patients with locally advanced or metastatic Non-Small Cell Lung Cancer confirmed to carry the KRAS G12C mutation by an approved diagnostic test, who have already received at least one prior systemic therapy. It is prescribed by medical oncologists and thoracic oncology specialists experienced in biomarker-guided cancer therapy. A thorough medical assessment including KRAS G12C mutation testing, baseline liver function, and cardiac evaluation is required before initiating treatment.

Manufacturer: Everest Pharmaceuticals Ltd.

Everest Pharmaceuticals Ltd. is a vertically integrated pharmaceutical company based in Dhaka, Bangladesh, focused on complex, technology-driven specialty medicines across oncology, nephrology, and virology. Operating under Bangladesh’s TRIPS/Doha Declaration exemption for least-developed countries, Everest manufactures advanced generics such as Sotoxen under WHO-GMP-compliant standards, with the stated mission of making high-cost, life-saving medicines accessible and affordable to patients around the world. Sotoxen is one of Everest’s specialty precision-oncology products, offering a bioequivalent alternative to Lumakras by Amgen at a fraction of the cost.

Global Supplier: Mediaid Pharmacy with Worldwide Shipping

Mediaid Pharmacy is a trusted global supplier of specialty and oncology medications. We ensure Sotoxen (Sotorasib) is accessible to patients and healthcare providers worldwide through reliable worldwide shipping. Whether you are located in South Asia, the Middle East, Africa, Europe, or beyond, Mediaid Pharmacy provides fast and reliable delivery with full order support. Contact us directly via WhatsApp, phone, or WeChat for pricing, availability, and delivery enquiries.

Why Choose Sotoxen (Sotorasib) from Mediaid Pharmacy?

Sotoxen represents a landmark advance in precision lung cancer therapy, targeting a mutation once considered impossible to drug. As the generic equivalent of Lumakras by Amgen, it delivers the same active ingredient, Sotorasib, with the same proven KRAS G12C-inhibition mechanism at a dramatically more affordable price. Manufactured by Everest Pharmaceuticals Ltd. under WHO-GMP-compliant standards and distributed globally by Mediaid Pharmacy, Sotoxen gives patients worldwide access to advanced precision lung cancer therapy without the financial burden of brand-name alternatives. For patients and physicians seeking a proven, affordable, and accessible Sotorasib option with worldwide delivery, Sotoxen from Mediaid Pharmacy is the trusted choice.

Frequently Asked Questions About Sotoxen (Sotorasib)